Allevi Joins Johnson&Johnson's JPOD Philadelphia Community

As new applications continue to be developed within the Allevi community, we feel the responsibility to join larger ecosystems that connect us with more engineers, scientists, and physicians that can benefit from the power of Allevi’s solutions. Our first successful relationship with a broader ecosystem has been with VWR. They continue to help us introduce our platform to accelerate science around the world. Adding geometry to biology is becoming a standard to be able to generate accurate representations of the body outside the body. 

At Allevi, we are now ready to begin to understand how to translate our communities’ scientific discoveries into the breakthroughs of tomorrow. To do this we realize that we need to co-create solutions with those at the front lines who are bringing new drugs to market, fighting diseases at the bedside, and producing novel solutions for the healthcare system.

Therefore, we are excited to join the Johnson & Johnson Innovation, JLABS JPOD @ Philadelphia community. We believe access to this ecosystem helps us connect with those who understand how Allevi’s applications can serve the healthcare industry. These interactions will guide our community today and in the future. Together we can target healthcare’s biggest needs by creating more accurate, predictable 3D biology models.

As we continue to collaborate with the Johnson & Johnson Innovation community, we will look forward to receiving mentorship, brainstorming with great minds in the industry, and continuing to grow Allevi. It takes a village to raise a company and we are happy to have the JLABS village help us reach new heights.

On the Horizon: The First 3D Bioprinted Organ Transplant

3D bioprinters are steadily becoming a staple in research and health settings around the world—and Russian researchers from the 3D Bioprinting Solutions lab just outside Moscow are proving just how powerful they can be.

Their aim is to perform the first transplant of a 3D bioprinted organ. The organ of choice? A thyroid gland, due to its relative simplicity. If the operation succeeds and the thyroid is accepted by the patient’s body, the lab will work on transplanting a 3D bioprinted kidney in the coming years.

3d bioprinted organ transplant.jpg

The thyroid will be printed using fat-derived stem cells, and a hydrogel. Since the patient’s own stem cells will be used, the hope is that the resulting thyroid gland will not be rejected by their body.

Head of research at the lab, Vladimir Mironov, is excited by the prospect of applying this technology to kidneys: “The one who will be the first to print and then successfully transplant the kidney to the patient - who will stay alive - will for sure get a Nobel prize.”

The whole 3D bioprinting community, including us here at Allevi, has high hopes for the operation. It’s success could be a huge watershed moment in medical history. 

Scientists Create Beating Heart Tissue in a Lab Dish

Check out the amazing work that our collaborators, Dr. Kevin Costa and his lab, are doing at Mount Sinai!

The Frontier of Clear 3D Tissues

At Allevi, our goal is to build tools that will allow scientists to explore questions in 3D culture. Yet, while this approach brings us closer to achieving the physiological microenvironments that cells experience, it makes it more difficult for us to observe what cells are doing deeper within these 3D constructs.

Molly Boutin, a graduate student at Brown University, may have come up with a possible solution to this dilemma. Using a clearing agent, ClearT2, which can reduce the scattering of light coming from fluorescent cells within the tissue. By doing so, fluorescent cells were visualized while maintaining the size of the tissue construct.

Fig 5F: ClearT2 protocol was successfully applied to spheres composed of various neural cell types. Cortical neurons shown in this figure (Boutin 2014)

Fig 5F: ClearT2 protocol was successfully applied to spheres composed of various neural cell types. Cortical neurons shown in this figure (Boutin 2014)

While this technique was used for scaffold-free tissues, it could be adapted to 3D bioprinting by using scaffolding that can be tuned to degrade over time and in response to certain non-toxic treatments as well as by proteases produced by the encapsulated cells as they deposit their own extracellular matrix.

This field is gaining more and more momentum everyday and we’re so excited to be at the front of this wave!